Sign In
Buy ANIP
$79.24
-1.19 (-1.48%)
At Close: Jul 31, 2026
AYAL Capital Advisors Ltd Sells 6,715 Shares of ANI Pharmaceuticals, Inc. $ANIP
03:55am, Saturday, 13'th Dec 2025
AYAL Capital Advisors Ltd lessened its position in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 10.1% during the second quarter, according to the company in its most recent 13F filing with the SEC. The
ANI (ANIP) is an Incredible Growth Stock: 3 Reasons Why
01:45pm, Thursday, 04'th Dec 2025
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Expert retina and uveitis specialists will help support the growth and innovation of ANI's ophthalmology and retina franchise for a meaningful impact on patients Expert retina and uveitis specialists
ANI Pharmaceuticals Announces Board Transition
06:50am, Monday, 01'st Dec 2025
Patrick D. Walsh steps down as Chairman and will complete his current term as Board member Thomas J. Haughey has been unanimously elected to serve as the next Chairman of the Board
ANIP vs. AMRX: Which Niche Drugmaker Is the Better Pick?
12:00pm, Friday, 28'th Nov 2025
ANI Pharmaceuticals' rare-disease momentum, led by surging Cortrophin Gel sales, sets up a stronger growth profile than its diversified rival.
Is ANI Pharmaceuticals (ANIP) Stock Outpacing Its Medical Peers This Year?
10:41am, Friday, 28'th Nov 2025
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Advantage Alpha Capital Partners LP Cuts Stock Position in ANI Pharmaceuticals, Inc. $ANIP
03:44am, Friday, 28'th Nov 2025
Advantage Alpha Capital Partners LP cut its position in ANI Pharmaceuticals, Inc. (NASDAQ: ANIP) by 22.0% in the undefined quarter, according to its most recent disclosure with the SEC. The fund owned
ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference
06:50am, Tuesday, 25'th Nov 2025
PRINCETON, N.J., Nov. 25, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that Nikhil Lalwani, Chief Executive Officer, will participate in a fir
Here's How ANIP's Rare Disease Portfolio Is Driving Top-line Growth
10:10am, Friday, 21'st Nov 2025
ANI Pharmaceuticals' rare disease surge, led by Cortrophin Gel, drives major 2025 revenue gains despite softer ophthalmology sales.
ANI (ANIP) Loses 15% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
10:36am, Wednesday, 19'th Nov 2025
The heavy selling pressure might have exhausted for ANI (ANIP) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in rev
3 Reasons Why Growth Investors Shouldn't Overlook ANI (ANIP)
01:45pm, Tuesday, 18'th Nov 2025
ANI (ANIP) is well positioned to outperform the market, as it exhibits above-average growth in financials.
ANI (ANIP) Upgraded to Strong Buy: Here's What You Should Know
01:01pm, Tuesday, 18'th Nov 2025
ANI (ANIP) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
ANI Pharmaceuticals Stock Surges 53% YTD: Time to Buy or Sell?
09:46am, Friday, 14'th Nov 2025
ANIP's 53% YTD surge fuels strong 2025 financial performance, a raised outlook and powerful momentum in its rare disease portfolio.
Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year?
10:41am, Wednesday, 12'th Nov 2025
Here is how ANI Pharmaceuticals (ANIP) and Black Diamond (BDTX) have performed compared to their sector so far this year.
Should Value Investors Buy ANI Pharmaceuticals (ANIP) Stock?
10:41am, Wednesday, 12'th Nov 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
